Shield Therapeutics Delivers Robust 2024 Revenue Growth and Expands Global Presence of ACCRUFeR®

PUBLISHED: Apr 24 2025 @ 03:09 | Comments (0) | More info about Fiona Craig

Shield Therapeutics plc (LSE:STX) posted impressive financial results for 2024, with net revenue climbing to $32.3 million—propelled by a 153% surge in sales of its flagship iron deficiency treatment, ACCRUFeR®. The company bolstered its financial foundation with a $10 million equity raise, positioning itself to reach cash flow breakeven by the end of 2025.

Shield made major strides in international expansion, with ACCRUFeR® gaining regulatory approvals and launching in Canada, while progressing filings in key markets like Korea and China. The company also marked a clinical milestone by completing a successful Phase 3 trial for its pediatric formulation, affirming both efficacy and safety in younger patients.

About Shield Therapeutics plc

Shield Therapeutics is a commercial-stage pharmaceutical company dedicated to the treatment of iron deficiency. Its core product, ACCRUFeR® (known as FeRACCRU® in Europe), is an oral ferric maltol therapy developed for patients with low iron levels. Through partnerships with Viatris in the U.S. and other licensing arrangements globally, Shield continues to expand its market footprint across North America, Europe, and Asia.

Year-to-Date Share Performance: -12.96%
Average Daily Trading Volume: 2,551,016 shares
Technical Sentiment: Bullish (Buy Signal)
Market Capitalization: £25 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.